摩根大通会后报告

The highlights from the most influential summit of the year.Bringing healthcare into focus. Summary The 42nd annual J.P. Morgan Healthcare Conference (JPM) was held in San Francisco, CA over8–11 January 2024. This report collates the daily presentation highlights from the conferencein a single destination. A complete list of events and catalysts that were announced or updatedis included as a supplement to the report. About the Author Biomedtrackeris an independent research service that offers proprietary clinicalassessments and patient-based revenue forecasts of developmental drugs within acomprehensive and intuitive drug information database. Clients from the pharmaceutical,biotech, and investment industries rely on Biomedtracker for its insight on the likelihood ofapproval, commercial potential, and future data and regulatory catalysts for drugs within thecompetitive landscape of every important disease and indication. Over the last several years,Biomedtracker has become the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide. For moreinformation on getting direct access to Biomedtracker, please emailclientservices@citeline.com. Disclaimer Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company This report is published by Pharma Intelligence (the Publisher). This report containsinformation from reputable sources and although reasonable efforts have been made topublish accurate information, you assume sole responsibility for the selection, suitability anduse of this report and acknowledge that the Publisher makes no warranties (either express orimplied) as to, nor accepts liability for, the accuracy or fitness for a particular purpose of theinformation or advice contained herein. The Publisher wishes to make it clear that any views oropinions expressed in this report by individual authors or contributors are their personal viewsand opinions and do not necessarily reflect the views/opinions of the Publisher. Table of Contents Summary.................................................................................................................. 2About the Author ....................................................................................................... 2Disclaimer................................................................................................................. 2Mega Cap.................................................................................................................. 7AbbVie................................................................................................................... 7Novartis ................................................................................................................. 8Novo Nordisk .......................................................................................................... 9Large Cap ............................................................................................................... 10Alnylam Pharmaceuticals......................................................................................... 10Amgen................................................................................................................. 11Argenx................................................................................................................. 12Baxter ................................................................................................................. 13Becton, Dickinson and Company ............................................................................... 14BeiGene ............................................................................................................... 15Bristol Myers Squibb............................................................................................... 16Cytokinetics .......................................................................................................... 17Genmab ............................................................................................................... 18Gilead.................................................................................................................. 19GSK .................................................................................................................... 20H. Lundbeck ......................................................................................................... 20Incyte.................................................................................................................. 21Legend Biotech...................................................................................................... 22Neurocrine Biosciences ........................................................................................... 24Regeneron............................................................................................................ 25Sanofi......